Melissa Perlman, DPM
Foot Surgery · Pembroke Pines, FLNPI 1245271386
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 335 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 34 manufacturers reported payments, led by Smith+Nephew at 31.8% of the total. Among foot surgery clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 335 payments — averaging $22.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Smith+Nephew$2K
- Organogenesis Inc.$1K
- Integra Lifesciences Corporation$707
- Stryker$616
- Aroa Biosurgery Incorporated$358
- Polynovo North America LLC$295
- plus $2K from 28 others
Across 14 payments — averaging $8721.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Royal Biologics, Inc.$122K
What the payments were for
- Speaking & faculty fees$811%
- Food & beverage$7,32999%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Smith+Nephew | 161 | $2,355 |
| Organogenesis Inc. | 63 | $1,236 |
| Integra Lifesciences Corporation | 34 | $707 |
| Stryker(2 entities) | 5 | $616 |
| Aroa Biosurgery Incorporated | 10 | $358 |
| Polynovo North America LLC | 14 | $295 |
| Paratek Pharmaceuticals, Inc. | 6 | $254 |
| Amgen | 3 | $159 |
| Trice Medical, Inc. | 2 | $159 |
| IBSA Pharma Inc. | 2 | $145 |
| Kerecis Limited | 3 | $137 |
| Derma Sciences, Inc. | 2 | $132 |
| Biotissue Holdings Inc. | 3 | $130 |
| Heron Therapeutics, Inc. | 1 | $72 |
| AbbVie | 3 | $69 |
| Treace Medical Concepts, Inc. | 1 | $67 |
| KCI USA, Inc. | 3 | $65 |
| HNM Stainless, LLC | 1 | $55 |
| Biocomposites Inc | 1 | $53 |
| Nevro Corp. | 3 | $53 |
| Access Pro Medical, LLC | 1 | $30 |
| Globus Medical | 1 | $29 |
| Acera Surgical, Inc. | 1 | $26 |
| Reprise Biomedical, Inc. | 1 | $26 |
| Orthofix Medical, Inc. | 1 | $25 |
| Medtronic | 1 | $24 |
| Philips North America LLC | 1 | $24 |
| Nabriva Therapeutics, PLC | 1 | $22 |
| Solventum Corporation | 1 | $18 |
| DJO, LLC | 1 | $17 |
| Bioventus LLC | 1 | $14 |
| Baxter Healthcare | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Acell, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INFINITY ADAPTIS$193
- INFINITY$172
- PROPHECY$165
- AMNIOEXCEL$129
- TCC-EZ$129
- PRIMATRIX$129
- IDRT$129
- OMNIGRAFT$129
- Dermagraft$125
- Licart$125
- NUZYRA$125
- KRYSTEXXA$117
- PuraPly AM$111
How this compares
$7,410 in reported general payments places this provider in the 90th percentile of 107 foot surgery providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SantylCollagenase Clostridium Hist. | 50 | $51,700 |
| RegranexBecaplermin | 15 | $23,756 |
| Ciclopirox | 204 | $3,827 |
| Ketoconazole | 79 | $2,406 |
| Mupirocin | 240 | $1,680 |
| CiclopiroxCiclopirox Olamine | 42 | $877 |
| Minocycline Hcl | 78 | $693 |
| Ammonium Lactate | 28 | $401 |
| Meloxicam | 31 | $81 |
| Methylprednisolone | 15 | $67 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Smith+NephewSantyl, Regranex | $2,355 | $75,45665 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 107 foot surgery providers in Florida.
Other foot surgery in Pembroke Pines
- Karen LeePembroke Pines$12K
- Larry HodsonPanama City$413K
- Bret BrennanTampa$60K
- Bradley HerbstJacksonville$20K
- Amy DunetzAventura$14K
- Than Binh NguyenTampa$13K
- Orlando CedenoJupiter$13K
- Nicole GortaireSt Augustine$11K
- Alix CharlesPlantation$8K
- Allison GuyenMiami Beach$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.